US 12,110,286 B2 · Benzimidazolone derived inhibitors of BCL6

Abstract

The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, as shown below:

wherein:
X1 is selected from N or CRa, wherein Ra is selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2-4C)alkenyl, (2-4C)alkynyl, nitro, cyano or NRbRc, wherein Rb and Rc are independently selected from hydrogen or (1-2C)alkyl;
X2 is selected from N or CRd, wherein Rd is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;
R1 is a group of the formula:
-L-Z
wherein:
L is absent or (1-2C)alkylene;
and
Z is (1-6C)alkyl, (3-6C)cycloalkyl or 4 to 7 membered heterocyclyl;
wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, NRgRh or ORg;
wherein Rg and Rh are each independently selected from hydrogen or (1-2C)alkyl;
R2 is selected from:
(i) a group of the formula:
wherein:
denotes the point of attachment;
W1 is selected from CR4R5 or C(O), wherein R4 and R5 are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1-2C)alkyl;
or
R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy;
W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)R1, SO2R1, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRlRm, wherein Rl and Rm are independently selected from hydrogen or (1-4C)alkyl, and wherein:
R6 is selected from hydroxy, amino, or (1-2C)alkoxy;
R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula:
—Y2-L2-Z2
wherein:
Y2 is absent or selected from O, N(Rn), S, SO, SO2, C(O), C(O)O, OC(O), C(O)N(Rn), N(Rn)C(O), S(O)2N(Rn), or N(Rn)SO2, wherein Rn is selected from hydrogen or (1-2C)alkyl;
L2 is absent or (1-2C)alkylene;
and
Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl;
wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro, hydroxy, C(O)Ro, C(O)ORo, OC(O)Ro, C(O)N(Ro)Rp, or NRoC(O)Rp, wherein Ro and Rp are independently selected from hydrogen or (1-4C)alkyl;
and
R8 is selected from (1-2C)alkyl, —C(O)ORq, ORq, or a 5-membered heteroaryl, wherein Rq is selected from hydrogen or (1-2C)alkyl;
or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxyl;
or
(ii) a group of the formula:
wherein:
denotes the point or attachment;
ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1-2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy;
W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, (1-4C)haloalkyl, (1-4C)hydroxyalkyl, —C(O)—CH3 or —C(O)ORab, wherein Rab is (1-4C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, —C(O)ORac, —NRacRad, phenyl or a 5-membered heteroaryl, wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl;
and
R3 is selected from:
i) a group of Formula A shown below:
wherein:
denotes the point of attachment,
Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;
R9 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3;
R10 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:
-Y3-Z3
wherein:
Y3 is absent or O, N(Rs)(CRsRt)q1 (where q1 is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), C(O)N(Rs), N(Rs)C(O), N(Rs)C(O)N(Rt), N(Rs)C(O)O, OC(O)N(Rs), S(O)2N(Rs), or N(Rs)SO2, wherein Rs and Rt are each independently selected from hydrogen or (1-4C)alkyl;
and
Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, heteroaryl or 4 to 11-membered heterocyclyl;
wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl;
and/or Z3 is optionally further substituted by a group of the formula:
-LZ-WZ
wherein:
LZ is absent or a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo;
and
WZ is aryl, heteroaryl, 4- to 7-membered heterocyclyl, 3- to 6-membered carbocyclyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(O)Rxa, COORxa, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl;
and wherein each aryl, heteroaryl, 4- to 7-membered heterocyclyl or 3- to 6-membered carbocyclyl is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, amino, cyano or hydroxy;
ii) a group of Formula B shown below:
wherein:
denotes the point of attachment;
Xc, Xd and Xe are independently selected from N, CH, CF, CCl, C—CN or CCH3;
R11 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula:
-Y5-Z5
wherein:
Y5 is absent or O, N(Rw), C(O), C(O)O, OC(O), C(O)N(Rw), N(Rw)C(O), N(Rw)C(O)N(Rx), N(Rw)C(O)O, OC(O)N(Rw), S(O)2N(Rw), or N(Rw)SO2, wherein Rw and Rx are each independently selected from hydrogen or (1-4C)alkyl;
and
Z5 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl;
wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, or ORy, wherein Ry and Rz are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl;
or
iii) a group of Formula C shown below:
wherein:
denotes the point of attachment;
R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, CH2F, CF2H or CF3;
Xf and Xg are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1-2C)haloalkyl or (1-2C)haloalkoxy;
Xh, Xi and Xj are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy;
with the proviso that:
(i) when R3 is a group of Formula B, no more than two of Xc, Xd and Xe are nitrogen;
and
(ii) when R3 is a group of Formula C, no more than three of Xf, Xg, Xh, Xi and Xj are nitrogen.

77 more elements

Benzimidazolone derived inhibitors of BCL6

Life of this patent

Benzimidazolone derived inhibitors of BCL6

Life of this patent

Abstract

Claims15